Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer

Molecular portraits of human breast tumours

Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938

Prospective identification of tumorigenic breast cancer cells

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672

Identification of human brain tumour initiating cells

Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864

Mutational landscape and significance across 12 major cancer types

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419

Ki67 expression in breast cancer: Correlation with prognostic markers and clinicopathological parameters in Saudi patients

Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087

ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome

Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012

Identification and expansion of human colon-cancer-initiating cells

Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836

Trastuzumab emtansine for HER2-positive advanced breast cancer

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429

Identification of Pancreatic Cancer Stem Cells

Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863

Prospective Identification of Tumorigenic Prostate Cancer Stem Cells

Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,820

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775

In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells

Dontu, G., Abdallah, W. M., Foley, J. M., Jackson, K. W., Clarke, M. F., Kawamura, M. J., & Wicha, M. S. (2003) · Genes & Development · doi:10.1101/gad.1061803 · Cited by 2,406

A restricted cell population propagates glioblastoma growth after chemotherapy

Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354

The causes and consequences of genetic heterogeneity in cancer evolution

Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262

Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry

Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M. G., Pe'er, J., Trent, J. M., Meltzer, P. S., & Hendrix, M. J. C. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65173-5 · Cited by 2,043

Generation of a functional mammary gland from a single stem cell

Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900

Efficient tumour formation by single human melanoma cells

Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794

Identification and expansion of the tumorigenic lung cancer stem cell population

Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C., & De Maria, R. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402283 · Cited by 1,707

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649

Purification and unique properties of mammary epithelial stem cells

Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., Li, H. I., & Eaves, C. J. (2006) · Nature · doi:10.1038/nature04496 · Cited by 1,559

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · cited 1×

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., et al. (2010) · Nature · doi:10.1038/nature09557 · Cited by 1,379

An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation

Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374

The Response of CD24 −/low /CD44 + Breast Cancer–Initiating Cells to Radiation

Phillips, T. M., McBride, W. H., & Pajonk, F. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj495 · Cited by 1,309

Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors

Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293

Hedgehog Signaling and Bmi-1 Regulate Self-renewal of Normal and Malignant Human Mammary Stem Cells

Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0054 · Cited by 1,244

Tumour heterogeneity in the clinic

Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211

Genome remodelling in a basal-like breast cancer metastasis and xenograft

Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139

A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing

Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130

Lineage Tracing Reveals Lgr5 + Stem Cell Activity in Mouse Intestinal Adenomas

Schepers, A. G., Snippert, H. J., Stange, D. E., van den Born, M., van Es, J. H., van de Wetering, M., & Clevers, H. (2012) · Science · doi:10.1126/science.1224676 · Cited by 1,072

Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties

Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Göktuna, S. I., Ziegler, P. K., Canli, O., Heijmans, J., Huels, D. J., Moreaux, G., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.012 · Cited by 1,068

Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts

Liu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-Trevino, R., Shang, L., McDermott, S. P., Landis, M. D., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.11.009 · Cited by 1,053

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006

Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970

Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State

Guo, W., Keckesova, Z., Donaher, J. L., Shibue, T., Tischler, V., Reinhardt, F., Itzkovitz, S., Noske, A., Zürrer-Härdi, U., Bell, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.008 · Cited by 957

Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity

Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 876

Distinct stem cells contribute to mammary gland development and maintenance

Van Keymeulen, A., Rocha, A. S., Ousset, M., Beck, B., Bouvencourt, G., Rock, J., Sharma, N., Dekoninck, S., & Blanpain, C. (2011) · Nature · doi:10.1038/nature10573 · Cited by 854

Reconstruction of functionally normal and malignant human breast tissues in mice

Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J. W., Carey, L., Richardson, A., & Weinberg, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401064101 · Cited by 804

Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798

BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells

Molyneux, G., Geyer, F. C., Magnay, F.-A., McCarthy, A., Kendrick, H., Natrajan, R., MacKay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.010 · Cited by 794

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009) · Breast Cancer Research · doi:10.1186/bcr2333 · Cited by 736

Defining the mode of tumour growth by clonal analysis

Driessens, G., Beck, B., Caauwe, A., Simons, B. D., & Blanpain, C. (2012) · Nature · doi:10.1038/nature11344 · Cited by 717

Metastatic Stem Cells: Sources, Niches, and Vital Pathways

Oskarsson, T., Batlle, E., & Massagué, J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.002 · Cited by 708

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., Margolick, J. B., Liotta, L. A., Petricoin, E., & Zhang, Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702596104 · Cited by 698

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1408 · Cited by 685

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

Marusyk, A., Tabassum, D. P., Altrock, P. M., Almendro, V., Michor, F., & Polyak, K. (2014) · Nature · doi:10.1038/nature13556 · Cited by 597

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., Hanada, R., Joshi, P. A., Aliprantis, A., Glimcher, L., et al. (2010) · Nature · doi:10.1038/nature09387 · Cited by 592

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590

Molecular Stratification of Triple-Negative Breast Cancers

Perou, C. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-61 · Cited by 582

Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice

Friedmann-Morvinski, D., Bushong, E. A., Ke, E., Soda, Y., Marumoto, T., Singer, O., Ellisman, M. H., & Verma, I. M. (2012) · Science · doi:10.1126/science.1226929 · Cited by 562

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

Korkaya, H., Paulson, A., Iovino, F., & Wicha, M. S. (2008) · Oncogene · doi:10.1038/onc.2008.207 · Cited by 556

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population

Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538

Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling

Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523

Transdifferentiation of glioblastoma cells into vascular endothelial cells

Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R. M., Kesari, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016030108 · Cited by 515

In situ identification of bipotent stem cells in the mammary gland

Rios, A. C., Fu, N. Y., Lindeman, G. J., & Visvader, J. E. (2014) · Nature · doi:10.1038/nature12948 · Cited by 509

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479

Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation

Yao, D., Dai, C., & Peng, S. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0568 · Cited by 455

Epigenetic programming and reprogramming during development

Cantone, I., & Fisher, A. G. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2489 · Cited by 437

A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis

Wagenblast, E., Soto, M., Gutiérrez-Ángel, S., Hartl, C. A., Gable, A. L., Maceli, A. R., Erard, N., Williams, A. M., Kim, S. Y., Dickopf, S., et al. (2015) · Nature · doi:10.1038/nature14403 · Cited by 433

HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426

Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?

Pantel, K., & Alix-Panabières, C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2030 · Cited by 409

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity

Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354

Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes

Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343

A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability

Eirew, P., Stingl, J., Raouf, A., Turashvili, G., Aparicio, S., Emerman, J. T., & Eaves, C. J. (2008) · Nature Medicine · doi:10.1038/nm.1791 · Cited by 339

A clinically relevant gene signature in triple negative and basal-like breast cancer

Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhaeberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3035 · Cited by 338

Sox2 promotes tamoxifen resistance in breast cancer cells

Piva, M., Domenici, G., Iriondo, O., Rábano, M., Simões, B. M., Comaills, V., Barredo, I., López‐Ruiz, J. A., Zabalza, I., Kypta, R., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303411 · Cited by 328

PIK3CAH1047R induces multipotency and multi-lineage mammary tumours

Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015) · Nature · doi:10.1038/nature14669 · Cited by 327

CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells

Sleeman, K. E., Kendrick, H., Ashworth, A., Isacke, C. M., & Smalley, M. J. (2005) · Breast Cancer Research · doi:10.1186/bcr1371 · Cited by 320

Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland

Shehata, M., Teschendorff, A., Sharp, G., Novcic, N., Russell, I. A., Avril, S., Prater, M., Eirew, P., Caldas, C., Watson, C. J., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3334 · Cited by 306

The wnt/β‐catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer

King, T. D., Suto, M. J., & Li, Y. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23350 · Cited by 296

Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling

Fillmore, C. M., Gupta, P. B., Rudnick, J. A., Caballero, S., Keller, P. J., Lander, E. S., & Kuperwasser, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007863107 · Cited by 283

Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors

Schott, A. F., Landis, M. D., Dontu, G., Griffith, K. A., Layman, R. M., Krop, I., Paskett, L. A., Wong, H., Dobrolecki, L. E., Lewis, M. T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3326 · Cited by 277

CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome

Idowu, M. O., Kmieciak, M., Dumur, C., Burton, R. S., Grimes, M. M., Powers, C. N., & Manjili, M. H. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.05.005 · Cited by 264

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Dave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7814 · Cited by 252

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Luu, T. H., Morgan, R. J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D. D., Doroshow, J. H., Gandara, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0122 · Cited by 237

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

Ithimakin, S., Day, K. C., Malik, F., Zen, Q., Dawsey, S. J., Bersano-Begey, T. F., Quraishi, A. A., Ignatoski, K. W., Daignault, S., Davis, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3349 · Cited by 236

TGF-β-Id1 Signaling Opposes Twist1 and Promotes Metastatic Colonization via a Mesenchymal-to-Epithelial Transition

Stankic, M., Pavlovic, S., Chin, Y., Brogi, E., Padua, D., Norton, L., Massagué, J., & Benezra, R. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.014 · Cited by 221

Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Giordano, A., Gao, H., Anfossi, S., Cohen, E., Mego, M., Lee, B.-N., Tin, S., De Laurentiis, M., Parker, C. A., Alvarez, R. H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0460 · Cited by 219

DNA Mismatch Repair Gene Polymorphisms Affect Survival in Pancreatic Cancer

Dong, X., Li, Y., Hess, K. R., Abbruzzese, J. L., & Li, D. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0127 · Cited by 216

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., Singer, C. F., Lowe, E. S., Watkins, C. L., & Carmichael, J. (2013) · Breast Cancer Research · doi:10.1186/bcr3484 · Cited by 184

Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer

Magnani, L., Stoeck, A., Zhang, X., Lánczky, A., Mirabella, A. C., Wang, T.-L., Gyorffy, B., & Lupien, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219992110 · Cited by 181

DNA Damage Repair Pathways in Cancer Stem Cells

Maugeri-Saccà, M., Bartucci, M., & De Maria, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1040 · Cited by 178

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer

Vignot, S., Frampton, G. M., Soria, J.-C., Yelensky, R., Commo, F., Brambilla, C., Palmer, G., Moro-Sibilot, D., Ross, J. S., Cronin, M. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7737 · Cited by 175

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

Holm, K., Grabau, D., Lövgren, K., Aradottir, S., Gruvberger-Saal, S., Howlin, J., Saal, L. H., Ethier, S. P., Bendahl, P.-O., Stål, O., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.06.002 · Cited by 161

Notch Signaling Pathway as a Therapeutic Target in Breast Cancer

Al-Hussaini, H., Subramanyam, D., Reedijk, M., & Sridhar, S. S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0677 · Cited by 154

Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches

Pan, Q., Li, Q., Liu, S., Ning, N., Zhang, X., Xu, Y., Chang, A. E., & Wicha, M. S. (2015) · Stem Cells · doi:10.1002/stem.2039 · Cited by 153

HER2 and Breast Cancer Stem Cells: More than Meets the Eye

Körkaya, H., & Wicha, M. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0260 · Cited by 120

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy

Thomas, S., Thurn, K. T., Biçaku, E., Marchion, D. C., & Münster, P. N. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1364-y · Cited by 114

Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk

Rajaram, R. D., Buric, D., Čaikovski, M., Ayyanan, A., Rougemont, J., Shan, J., Vainio, S. J., Yalcin-Ozuysal, Ö., & Brisken, C. (2015) · The EMBO Journal · doi:10.15252/embj.201490434 · Cited by 110

Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells

Hodges-Gallagher, L., Valentine, C. D., Bader, S. E., & Kushner, P. J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9459-6 · Cited by 108

Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling

Harrison, H., Simões, B. M., Rogerson, L., Howell, S. J., Landberg, G., & Clarke, R. B. (2013) · Breast Cancer Research · doi:10.1186/bcr3396 · Cited by 98

Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer

Jansen, M. P. H. M., Knijnenburg, T., Reijm, E. A., Simón, I., Kerkhoven, R. M., Droog, M., Velds, A., Laere, S. V., Dirix, L. Y., Alexi, X., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0704 · Cited by 90

Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity

Lamb, R., Lehn, S., Rogerson, L., Clarke, R. B., & Landberg, G. (2013) · Cell Cycle · doi:10.4161/cc.25403 · Cited by 89

Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor–Mediated Signaling

Biçaku, E., Marchion, D. C., Schmitt, M. L., & Münster, P. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2822 · Cited by 89

Estrogen Receptor-Alpha 36 Mediates Mitogenic Antiestrogen Signaling in ER-Negative Breast Cancer Cells

Zhang, X., Ding, L., Kang, L., & Wang, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030174 · Cited by 77

Intratumoral Heterogeneity in a Trp53 -Null Mouse Model of Human Breast Cancer

Zhang, M., Tsimelzon, A. I., Chang, C.-H., Fan, C., Wolff, A., Perou, C. M., Hilsenbeck, S. G., & Rosen, J. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1101 · Cited by 76

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells

Deng, H., Zhang, X., Wang, Μ., Zheng, H., Liú, L., & Wang, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088034 · Cited by 72

CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer

Conley, S. J., Baker, T. L., Burnett, J., Theisen, R., Lazarus, D. D., Peters, C. G., Clouthier, S. G., Eliasof, S. D., & Wicha, M. S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3349-8 · Cited by 69

Improved survival of patients with primary distant metastatic breast cancer in the period of 1995–2008. A nationwide population-based study in the Netherlands

Ruiterkamp, J., Ernst, M. F., de Munck, L., der Loo, M. V. D. H., Bastiaannet, E., van de Poll-Franse, L. V., Bosscha, K. P., Tjan‐Heijnen, V. C. G., & Voogd, A. C. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1349-x · Cited by 68

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

Wagner, D., Thomssen, C., Haerting, J., & Unverzagt, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008941.pub2 · Cited by 66

ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype

Junankar, S. R., Baker, L. A., Roden, D. L., Nair, R., Elsworth, B., Gallego‐Ortega, D., Lacaze, P. A., Cazet, A., Nikolić, I., Teo, W. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7548 · Cited by 63

The Therapeutic Implications of Plasticity of the Cancer Stem Cell Phenotype

Leder, K., Holland, E. C., & Michor, F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014366 · Cited by 59

Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Alamgeer, M., Ganju, V., Kumar, B., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3648 · Cited by 57

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

Park, Y. H., Jung, H. A., Choi, M. K., Chang, W., Choi, Y., Do, I.-G., Ahn, J. S., & Im, Y.-H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.757 · Cited by 48

Models of Breast Morphogenesis Based on Localization of Stem Cells in the Developing Mammary Lobule

Honeth, G., Schiavinotto, T., Vaggi, F., Marlow, R., Kanno, T., Shinomiya, I., Lombardi, S., Buchupalli, B., Graham, R. A., Gazińska, P., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.013 · Cited by 37

Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits

Pal, B., Chen, Y., Bert, A. G., Hu, Y., Sheridan, J. M., Beck, T. J., Shi, W., Satterley, K., Jamieson, P. R., Goodall, G. J., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0585-0 · Cited by 36

Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies

Fabi, A., Metro, G., Benedetto, A. D., Nisticò, C., Vici, P., Melucci, E., Antoniani, B., Perracchio, L., Sperduti, I., Milella, M., et al. (2010) · Oncology · doi:10.1159/000312656 · Cited by 35

Anatomical localization of progenitor cells in human breast tissue reveals enrichment of uncommitted cells within immature lobules

Arendt, L. M., Keller, P. J., Skibinski, A., Goncalves, K., Naber, S. P., Buchsbaum, R. J., Gilmore, H. L., Come, S. E., & Kuperwasser, C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0453-3 · Cited by 30

Targeting met mediated epithelial‐mesenchymal transition in the treatment of breast cancer

Sylvester, P. W. (2014) · Clinical and Translational Medicine · doi:10.1186/s40169-014-0030-5 · Cited by 26

Visualization and targeting of LGR5+ human colon cancer stem cells

Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., Date, S., Sugimoto, S., Kanai, T., & Sato, T. (2017) · Nature · doi:10.1038/nature22081 · Cited by 728

Targeting Cancer Stemness in the Clinic: From Hype to Hope

Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.017 · Cited by 517

The multi-factorial nature of clinical multidrug resistance in cancer

Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528

Drug Resistance Driven by Cancer Stem Cells and Their Niche

Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., & Ochiya, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122574 · Cited by 508

Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells

Kröger, C., Afeyan, A., Mraz, J., Eaton, E. N., Reinhardt, F., Khodor, Y. L., Thiru, P., Bierie, B., Ye, X., Burge, C. B., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812876116 · Cited by 499